Drugs / 18F-deoxyglucose (FDG)
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| — | NCT02078141 | Jun 2014 → Jan 2018 | non-familial dilated cardiomyopathy | Nantes University Hospital | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | 18F-deoxyglucose (FDG) | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02078141 ↗ |
| Known as | 18F-fluorodeoxyglucose | “All patients will have with in 4 weeks after the MRI a 18F-fluorodeoxyglucose (FDG) PET.” NCT02078141 ↗ |
| Modality | Diagnostic / imaging agent | “18F-fluorodeoxyglucose (FDG) positron emission tomography (PET) may have application in a promising tool for identification of myocardial inflammation” NCT02078141 ↗ |